Evidence map›Paper›PMID 25922391›Full record

ArticlemBio2015

Thinking globally, acting locally: harnessing the immune system to deal with recalcitrant pathogens.

Michael W Russell

Open access · goldAbstract read
In one paragraph

Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael W RussellDepartments of Microbiology, Immunology, and Oral Biology, University at Buffalo, Buffalo, New York, USA russellm@buffalo.edu.
University at Buffalo, State University of New York · US

Funding

Therapy and Prophylaxis for Genital Tract InfectionR44AI104067 · NIAID · THERAPYX, INC. · PI AUCI, DOMINICK, RUSSELL, MICHAEL W · 2014 to 2022
$4.4M
Therapy and Prophylaxis for Genital Tract InfectionR43AI104067 · NIAID · THERAPYX, INC. · PI LIU, YINGRU · 2013 to 2013
$300k
Experimental Gonococcal VaccineR43AI115877 · NIAID · THERAPYX, INC. · PI LIU, YINGRU · 2015 to 2015
$271k
NIAID NIH HHS R43 AI104067NIAID NIH HHS R43 AI115877NIAID NIH HHS R43-AI115877NIAID NIH HHS R44 AI104067NIAID NIH HHS R44-AI104067
6 · The paper itself

Abstract

Traditional approaches to harnessing the immune system to confront infectious diseases depend on vaccines, which have generally proven highly effective, but for many infections these either are not available or are of limited effectiveness. Although antibiotic therapy has been extremely successful in reducing the burden of bacterial disease, the emergence of resistance among several important pathogens threatens to undermine this accomplishment, and despite some successes chemotherapeutic treatments for viral, fungal, and parasitic infections are more limited. Understanding the mechanisms whereby pathogens manipulate the immune system to favor their survival, or exploit weaknesses in host immunity, can lead to novel approaches for the treatment of infections by redirecting host immune responses against the pathogen. Such treatments may be most effectively applied at the mucosal locations which are frequently the sites of initial infection and may also suggest new approaches for vaccine development.

Indexed as

ImmunomodulationBacteriaBacterial InfectionsHumansImmune System

Identifiers

PMID25922391
PMCPMC4436072
OpenAlexW2122281236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.